Direkt zum Inhalt
Merck
  • Cell death-inducing cytotoxicity in truncated KCNQ4 variants associated with DFNA2 hearing loss.

Cell death-inducing cytotoxicity in truncated KCNQ4 variants associated with DFNA2 hearing loss.

Disease models & mechanisms (2021-10-09)
Takashi Kojima, Koichiro Wasano, Satoe Takahashi, Kazuaki Homma
ZUSAMMENFASSUNG

KCNQ4 encodes the homotetrameric voltage-dependent potassium ion channel Kv7.4, and is the causative gene for autosomal dominant nonsyndromic sensorineural hearing loss, DFNA2. Dominant-negative inhibition accounts for the observed dominant inheritance of many DFNA2-associated KCNQ4 variants. In addition, haploinsufficiency has been presumed as the pathological mechanism for truncated Kv7.4 variants lacking the C-terminal tetramerization region, as they are unlikely to exert a dominant-negative inhibitory effect. Such truncated Kv7.4 variants should result in relatively mild hearing loss when heterozygous; however, this is not always the case. In this study, we characterized Kv7.4Q71fs (c.211delC), Kv7.4W242X (c.725G>A) and Kv7.4A349fs (c.1044_1051del8) in heterologous expression systems and found that expression of these truncated Kv7.4 variants induced cell death. We also found similar cell death-inducing cytotoxic effects in truncated Kv7.1 (KCNQ1) variants, suggesting that the generality of our findings could account for the dominant inheritance of many, if not most, truncated Kv7 variants. Moreover, we found that the application of autophagy inducers can ameliorate the cytotoxicity, providing a novel insight for the development of alternative therapeutic strategies for Kv7.4 variants.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Doxycyclin -hyclat
Sigma-Aldrich
Necrostatin-1, Necrostatin-1, CAS 4311-88-0, is a cell-permeable, potent, and selective blocker of necroptosis (EC₅₀ = 494 nM in FADD-deficient Jurkat cells treated with TNF-α).
Sigma-Aldrich
Tunicamycin, Streptomyces lysosuperficus
Sigma-Aldrich
SBI-0206965, ≥98% (HPLC)
Sigma-Aldrich
Caspase-Inhibitor VI, Z-VAD-FMK, CAS 161401-82-7, is an irreversible pan caspase inhibitor. Does not require pretreatment with esterase for in vitro studies.